Last reviewed · How we verify
Radio-labeled rodatristat ethyl 600 mg
Radio-labeled rodatristat ethyl 600 mg is a Small molecule drug developed by Altavant Sciences GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | Radio-labeled rodatristat ethyl 600 mg |
|---|---|
| Sponsor | Altavant Sciences GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radio-labeled rodatristat ethyl 600 mg CI brief — competitive landscape report
- Radio-labeled rodatristat ethyl 600 mg updates RSS · CI watch RSS
- Altavant Sciences GmbH portfolio CI
Frequently asked questions about Radio-labeled rodatristat ethyl 600 mg
What is Radio-labeled rodatristat ethyl 600 mg?
Radio-labeled rodatristat ethyl 600 mg is a Small molecule drug developed by Altavant Sciences GmbH.
Who makes Radio-labeled rodatristat ethyl 600 mg?
Radio-labeled rodatristat ethyl 600 mg is developed by Altavant Sciences GmbH (see full Altavant Sciences GmbH pipeline at /company/altavant-sciences-gmbh).
What development phase is Radio-labeled rodatristat ethyl 600 mg in?
Radio-labeled rodatristat ethyl 600 mg is in Phase 1.